The deal could be worth an additional $850 million if Rodin’s drugs meet certain clinical and regulatory milestones and sales thresholds.
Alkermes said its acquisition of Rodin’s platform will allow it to potentially develop drugs to treat Alzheimers, Huntington’s disease, dementia and depression.
The deal gives Alkermes a potential path to growth after losing $165.6 million in revenue as of October and cutting 160 jobs.
Alkermes said it expects to complete the deal by the end of the month.
Read the full news release here.
More articles on pharmacy:
Drugmakers could lose $1T in sales and still be most profitable industry, analysis finds
CAR-T costs ‘not sustainable’ for hospitals, researchers say
How Walgreens, CVS see the future of pharmacy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.